Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium
Lung Cancer, 07/27/2012
Campbell NP et al. – This trial did not meet its pre–specified response endpoint. A higher cediranib dose level was associated with improved disease control, but this dose was poorly tolerated.